Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

A number of other equities research analysts also recently commented on the stock. Piper Jaffray Companies assumed coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They issued an “overweight” rating and a $14.00 target price for the company. BMO Capital Markets reissued an “outperform” rating and set a $13.00 price objective (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, July 26th. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th. HC Wainwright began coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They set a “buy” rating and a $15.00 price objective for the company. Finally, ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $10.88.

Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down 4.24% during trading on Friday, reaching $6.55. The company’s stock had a trading volume of 1,060,780 shares. The stock’s market cap is $334.40 million. Tetraphase Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.93. The firm has a 50 day moving average price of $6.31 and a 200-day moving average price of $7.31.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The firm had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same quarter in the previous year, the firm earned ($0.47) earnings per share. Tetraphase Pharmaceuticals’s revenue was up 28.2% on a year-over-year basis. On average, analysts expect that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Tetraphase Pharmaceuticals, Inc. (TTPH) Downgraded to “Hold” at Zacks Investment Research” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/22/tetraphase-pharmaceuticals-inc-ttph-downgraded-to-hold-at-zacks-investment-research.html.

In related news, insider Jacques Dumas sold 7,155 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $5.86, for a total value of $41,928.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. EcoR1 Capital LLC purchased a new stake in Tetraphase Pharmaceuticals in the 2nd quarter worth $4,516,000. State Street Corp lifted its stake in Tetraphase Pharmaceuticals by 6.4% in the 2nd quarter. State Street Corp now owns 725,094 shares of the biopharmaceutical company’s stock worth $5,165,000 after purchasing an additional 43,561 shares in the last quarter. PDT Partners LLC lifted its stake in Tetraphase Pharmaceuticals by 22.0% in the 2nd quarter. PDT Partners LLC now owns 191,952 shares of the biopharmaceutical company’s stock worth $1,369,000 after purchasing an additional 34,665 shares in the last quarter. Balyasny Asset Management LLC lifted its stake in Tetraphase Pharmaceuticals by 13.2% in the 2nd quarter. Balyasny Asset Management LLC now owns 246,300 shares of the biopharmaceutical company’s stock worth $1,756,000 after purchasing an additional 28,800 shares in the last quarter. Finally, Numeric Investors LLC lifted its stake in Tetraphase Pharmaceuticals by 1,363.3% in the 2nd quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock worth $5,379,000 after purchasing an additional 702,812 shares in the last quarter. Institutional investors and hedge funds own 41.73% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.